Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice

Journal of Virology

Volumn 87, Issue 12, 2013, Pages 6748-6757

  Piper, Amanda ^a   Ribeiro, Mariana ^a   Brown, Dennis T ^a   Hernandez, Raquel ^a   Smith, Katherine M ^b   Briggs, Caitlin M ^b   Huitt, Emerson ^b   Nanda, Kavita ^b   Spears, Carla J ^b   Quiles, Michelle ^b   Thomas, Malcolm E ^b   Cullen, John ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b Arbovax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIKUNGUNYA FEVER VACCINE; GLYCOPROTEIN E2; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOOT EDEMA; HOST RANGE; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE SWELLING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROVOCATION TEST; VIREMIA; VIRUS ENVELOPE; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ALPHAVIRUS INFECTIONS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CHIKUNGUNYA VIRUS; HOST SPECIFICITY; HUMANS; MICE; MICE, INBRED C57BL; MUTATION; SEQUENCE DELETION; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS REPLICATION;

ARBOVIRUS; CHIKUNGUNYA VIRUS; HEXAPODA; MAMMALIA; MUS;

EID: 84878589169     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03357-12     Document Type: Article

References (68)

1. Thomas S, Rai J, John L, Gunther S, Drosten C, Pützer BM, Schaefer S. 2010. Functional dissection of the alphavirus capsid protease: sequence requirements for activity.Virol.J.7:327.
2. Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana- Seisdedos F, Desprès P, Michault A, Albert ML, Schwartz O. 2007. Characterization of reemerging Chikungunya virus. PLoS Pathog. 3:e89. doi:10.1371/journal.ppat.0030089.
3. Diallo M, Thonnon J, Traore-Lamizana M, Fontenille D. 1999. Vectors of Chikungunya virus in Senegal: current data and transmission cycles. Am. J. Trop. Med. Hyg. 60:281-286.
4. Delatte H, Paupy C, Dehecq JS, Thiria J, Failloux AB, Fontenille D. 2008. Aedes albopictus, vector of chikungunya and dengue viruses in Reunion Island: biology and control.Parasite.15:3-13.
5. Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17:1055-1065.
6. Peyrefitte CN, Bessaud M, Pastorino BA, Gravier P, Plumet S, Merle OL, Moltini I, Coppin E, Tock F, Daries W, Ollivier L, Pages F, Martin R, Boniface F, Tolou HJ, Grandadam M. 2008. Circulation of Chikungunya virus in Gabon, 2006-2007. J. Med. Virol. 80:430-433.
7. Rogers KM, Heise M. 2009. Modulation of cellular tropism and innate antiviral response by viral glycans.J. Innate Immun.1:405-412.
8. Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV. 2008. Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. Emerg. Infect. Dis.14:412-415.
9. Powers AM, Brault AC, Tesh RB, Weaver SC. 2000. Re-emergence of chikungunya and o'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J. Gen. Virol. 81:471- 479.
10. Weaver SC, Barrett AD. 2004. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat. Rev. Microbiol. 2:789-801.
11. WHO. 2007. Outbreak and spread of Chikungunya. Wkly. Epidemiol. Rec. 82:409-416.
12. Gérardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, Lenglet Y, Touret Y, Bouveret A, Grivard P, Le Roux K, Blanc S, Schuffenecker I, Couderc T, Arenzana-Seisdedos F, Lecuit M, Robillard PY. 2008. Multidisciplinary prospective study of mother-to-child Chikungunya virus infections on the island of La Réunion. PLoS Med. 5:e60. doi:10.1371/journal.pmed.0050060.
13. Fritel X, Rollot O, Gerardin P, Gauzere BA, Bideault J, Lagarde L, Dhuime B, Orvain E, Cuillier F, Ramful D, Samperiz S, Jaffar-Bandjee MC, Michault A, Cotte L, Kaminski M, Fourmaintraux A, Chikungunya- Mere-Enfant Team. 2010. Chikungunya virus infection during pregnancy, Reunion, France, 2006. Emerg. Infect. Dis. 16:418-425.
14. West J, Hernandez R, Ferreira D, Brown DT. 2006. Mutations in the endodomain of Sindbis virus glycoprotein E2 define sequences critical for virus assembly. J. Virol. 80:4458-4468.
15. Hafer A, Whittlesey R, Brown DT, Hernandez R. 2009. Differential incorporation of cholesterol by Sindbis virus grown in mammalian or insect cells. J. Virol. 83:9113-9121.
16. Hernandez R, Paredes A, Brown DT. 2008. Sindbis virus conformational changes induced by a neutralizing anti-E1 monoclonal antibody.J. Virol.82:5750-5760.
17. Hernandez R, Paredes A. 2009. Sindbis virus as a model for studies of conformational changes in a metastable virus and the role of conformational changes in in vitro antibody neutralisation. Rev. Med. Virol.9:257-272.
18. Suhrbier A, Jaffar-Bandjee MC, Gasque P. 2012. Arthritogenic alphaviruses- an overview. Nat. Rev. Rheumatol. 8:420-429.
19. Dubrulle M, Mousson L, Moutailler S, Vazeille M, Failloux A-B. 2009. Chikungunya virus and Aedes mosquitoes: saliva is infectious as soon as two days after oral infection. PLoS One 4:e5895. doi:10.1371/journal.pone .0005895.
20. Napoli C, Salcuni P, Pompa MG, Declich S, Rizzo C. 2012. Estimated imported infections of Chikungunya and dengue in Italy, 2008 to 2011.J. Travel Med. 19:294-297.
21. Queyriaux B, Armengaud A, Jeannin C, Couturier E, Peloux-Petiot F. 2008. Chikungunya in Europe.Lancet 371:723-724.
22. van den Hurk AF, Hall-Mendelin S, Pyke AT, Smith GA, Mackenzie JS. 2010. Vector competence of Australian mosquitoes for chikungunya virus. Vector Borne Zoonotic Dis. 10:489-495.
23. Gibney KB, Fischer M, Prince HE, Kramer LD, St. George K, Kosoy OL, Laven JJ, Staples JE. 2011. Chikungunya fever in the United States: a fifteen year review of cases. Clin. Infect. Dis. 52:e121-126. doi:10.1093/cid /ciq214.
24. Park JY, Lee YS, Kim BH, Park SM. 2008. Label-free detection of antibody-antigen interactions on (R)-lipo-diaza-18-crown-6 selfassembled monolayer modified gold electrodes. Anal. Chem.80:4986-4993.
25. Barrett AD, Stanberry LR (ed). 2009.Vaccines for biodefence and emerging and neglected diseases. Elsevier, Amsterdam, The Netherlands.
26. Coffey LL, Vasilakis N, Brault AC, Powers AM, Tripet F, Weaver SC. 2008. Arbovirus evolution in vivo is constrained by host alternation. Proc. Natl. Acad. Sci. U. S. A. 105:6970-6975.
27. Jozan M.1987. Of arboviruses, arthropods, and arthropod cell cultures: history and expectations, p 3-22. In Yunker C (ed), Arboviruses in arthropod cells in vitro. CRC Press, Boca Raton, FL.
28. Strauss JH, Strauss EG. 1994. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58:491-562.
29. Gibbons DL, Erk I, Reilly B, Navaza J, Kielian M, Rey FA, Lepault J. 2003. Visualization of the target-membrane-inserted fusion protein of Semliki Forest virus by combined electron microscopy and crystallography. Cell 114:573-583.
30. He L, Piper A, Meilleur F, Myles DA, Hernandez R, Brown DT, Heller WT. 2010. The structure of Sindbis virus produced from vertebrate and invertebrate hosts as determined by small-angle neutron scattering. J. Virol. 84:5270 -5276.
31. Casolari S, Briganti E, Zanotti M, Zauli T, Nicoletti L, Magurano F, Fortuna C, Fiorentini C, Grazia Ciufolini M, Rezza G. 2008. A fatal case of encephalitis associated with Chikungunya virus infection. Scand. J. Infect. Dis. 40:995-996.
32. Hernandez R, Sinodis C, Horton M, Ferreira D, Yang C, Brown DT. 2003. Deletions in the transmembrane domain of a Sindbis virus glycoprotein alter virus infectivity, stability, and host range. J. Virol. 77:12710- 12719.
33. Hernandez R, Lee H, Nelson C, Brown DT. 2000. A single deletion in the membrane-proximal region of the Sindbis virus glycoprotein E2 endodomain blocks virus assembly. J. Virol. 74:4220-4228.
34. McKnight KL, Simpson DA, Lin SC, Knott TA, Polo JM, Pence DF, Johannsen DB, Heidner HW, Davis NL, Johnston RE. 1996. Deduced consensus sequence of Sindbis virus strain AR339: mutations contained in laboratory strains which affect cell culture and in vivo phenotypes. J. Virol. 70:1981-1989.
35. Presley JF, Polo JM, Johnston RE, Brown DT. 1991. Proteolytic processing of the Sindbis virus membrane protein precursor PE2 is nonessential for growth in vertebrate cells but is required for efficient growth in invertebrate cells. J. Virol. 65:1905-1909.
36. Smith KM, Nanda K, Spears CJ, Ribeiro M, Vancini R, Piper A, Thomas GS, Thomas ME, Brown DT, Hernandez R. 2011. Structural mutants of dengue virus 2 transmembrane domains exhibit host-range phenotype. Virol. J. 8:289.
37. Smith KM, Nanda K, Spears CJ, Piper A, Ribeiro M, Quiles M, Briggs CM, Thomas GS, Thomas ME, Brown DT, Hernandez R, McCarl V. 2012. Testing of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacy. Am. J. Trop. Med. Hyg. 87:743-753.
38. Brown DT, Hernandez R. July 2003. U.S. patent 6,589,533.
39. Brown DT, Hernandez R. October 2001. U.S. patent 6,306,401.
40. Brown DT, Hernandez R. February 2008. U.S. patent 7,335,363.
41. Lakshmi V, Neeraja M, Subbalaxmi MVS, Parida MM, Dash PK, Santhosh SR, Rao PV. 2008. Clinical features and molecular diagnosis of Chikungunya fever from South India. Clin. Infect. Dis. 46:1436 -1442.
42. Mak C. 2012. Drug pipeline: 1Q12. Nat. Biotechnol. 30:383.
43. Tsetsarkin K, Higgs S, McGee CE, De Lamballerie X, Charrel RN, Vanlandingham DL. 2006. Infectious clones of Chikungunya virus (La Reunion isolate) for vector competence studies. Vector Borne Zoonotic Dis. 6:325-337.
44. Hernandez R, Sinodis C, Brown DT. 2010. Sindbis virus: propagation, quantification, and storage. Curr. Protoc. Microbiol. Chapter 15:Unit 15B.1. doi:10.1002/9780471729259.mc15b01s16.
45. Morrison TE, Oko L, Montgomery SA, Whitmore AC, Lotstein AR, Gunn BM, Elmore SA, Heise MT. 2011. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am. J. Pathol. 178:32- 40.
46. Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel- Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, Desprès P, Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M. 2008. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 4:e29. doi:10.1371 /journal.ppat.0040029.
47. Brown DT, Hernandez R. 2010. Host range mutants as vaccines for arthropod vectored viruses. Nova Acta Leopoldina NF 98:201-213.
48. Khan AH, Morita K, Parquet MC, Hasebe F, Mathenge EG, Igarashi A. 2002. Complete nucleotide sequence of Chikungunya virus and evidence for an internal polyadenylation site. J. Gen. Virol. 83:3075-3084.
49. Rice CM, Bell JR, Hunkapiller MW, Strauss EG, Strauss JH. 1982. Isolation and characterization of the hydrophobic COOH-terminal domains of the Sindbis virion glycoproteins. J. Mol. Biol. 154:355-378.
50. Ahlquist P, Strauss EG, Rice CM, Strauss JH, Haseloff J, Zimmern D. 1985. Sindbis virus proteins nsP1 and nsP2 contain homology to nonstructural proteins from several RNA plant viruses. J. Virol. 53:536 -542.
51. Hernandez R, Ferreira D, Sinodis C, Litton K, Brown DT. 2005. Single amino acid insertions at the junction of the Sindbis virus E2 transmembrane domain and endodomain disrupt virus envelopment and alter infectivity. J. Virol. 79:7682-7697.
52. Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE, Jr, Lupton HW. 1986. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4:157-162.
53. Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, Borland EM, Powers AM, Seymour R, Stinchcomb DT, Osorio JE, Frolov I, Weaver SC. 2011. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog. 7:e1002142. doi:10.1371/journal.ppat.1002142.
54. Wang E, Kim DY, Weaver SC, Frolov I. 2011. Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response. J. Virol. 85:9249 -9252.
55. Kim DY, Atasheva S, Foy NJ, Wang E, Frolova EI, Weaver S, Frolov I. 2011. Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype. J. Virol. 85:4363- 4376.
56. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ. 2010. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16:334 -338.
57. Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA, Ferraro B, Stabenow J, Vijayachari P, Sundaram SG, Muruganandam N, Sarangan G, Srikanth P, Khan AS, Lewis MG, Kim JJ, Sardesai NY, Muthumani K, Weiner DB. 2011. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl. Trop. Dis. 5:e928. doi:10.1371/journal.pntd.0000928.
58. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. 2012. Chikungunya virus and prospects for a vaccine. Expert Rev. Vaccines 11: 1087-1101.
59. Furio V, Garijo R, Duran M, Moya A, Bell JC, Sanjuán R. 2012. Relationship between within-host fitness and virulence in the vesicular stomatitis virus: correlation with partial decoupling. J. Virol. 86:12228- 12236.
60. Plotkin SA. 2009. Vaccines: the fourth century. Clin. Vaccine Immunol. 16:1709 -1719.
61. Kam YW, Simarmata D, Chow A, Her Z, Teng TS, Ong EK, Rénia L, Leo YS, Ng LF. 2012. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and longterm clinical protection. J. Infect. Dis. 205:1147-1154.
62. Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, Prost JF, Lecuit M. 2009. Prophylaxis and therapy for Chikungunya virus infection. J. Infect. Dis. 200:516 -523.
63. Linn ML, Mateo L, Gardner J, Suhrbier A. 1998. Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages. J. Virol. 72:5146 -5153.
64. Paessler S, Yun NE, Judy BM, Dziuba N, Zacks MA, Grund AH, Frolov I, Campbell GA, Weaver SC, Estes DM. 2007. Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection. Virology 367:307-323.
65. Thiboutot MM, Kannan S, Kawalekar OU, Shedlock DJ, Khan AS, Sarangan G, Srikanth P, Weiner DB, Muthumani K. 2010. Chikungunya: a potentially emerging epidemic? PLoS Negl. Trop. Dis. 4:e623. doi: 10.1371/journal.pntd.0000623.
66. Cavrini F, Gaibani P, Pierro AM, Rossini G, Landini MP, Sambri V. 2009. Chikungunya: an emerging and spreading arthropod-borne viral disease. J. Infect. Dev. Ctries. 3:744 -752.
67. Kamala T. 2007. Hock immunization: a humane alternative to mouse footpad injections. J. Immunol. Methods 328:204 -214.
68. s, Spataro N, Gaibani P, Cavrini F, Pierro A, Rossini G, Cameron MJ, Bermejo-Martin JF, Paquette SG, Xu L, Danesh A, Farooqui A, Borghetto I, Kelvin DJ, Sambri V, Rubino S. 2011. Inflammatory cytokine expression is associated with chikungunya virus resolution and symptom severity. PLoS Negl. Trop. Dis. 5:e1279. doi:10.1371/journal.pntd.0001279.